title: Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population.
abstract: BACKGROUND
  Apolipoprotein A5 (APOA5) plays an important role in plasma triacylglycerol (TG) homeostasis. Five polymorphisms (1131T>C, c.-3A>G, c.56C>G, IVS3+476G>A, and c.1259T>C) in the APOA5 gene define three common haplotypes (APOA5*1, APOA5*2, and APOA5*3) in Caucasian individuals. Our aim was to determine whether these haplotypes could modulate the postprandial response in young healthy males.
  
  
  METHODS
  Eighty-eight APO E3/3 volunteers [67 with (-1131T and 56C) APOA5*1 haplotype, 12 with (-1131C and 56C) APOA5*2 haplotype, and nine with (-1131T and 56G) APOA5*3 haplotype] underwent a fat load test consisting of the consumption of 1 g of fat per kilogram body weight and 60,000 IU vitamin A. Blood samples were taken at time 0, at every hour until the sixth hour, and at every 2.5 h until the 11th hour. Total plasma cholesterol (C) and TG, and C, TG, apolipoprotein B-100, apolipoprotein B-48, and retinyl palmitate in lipoprotein fractions were determined.
  
  
  RESULTS
  Subjects with the APOA5*2 and APOA5*3 haplotypes had a higher area under the curve of total plasma TG (P = 0.03), large TG-rich lipoprotein (TRL)-TG (P = 0.02), small TRL-TG (P = 0.04), small TRL-C (P = 0.04), large TRL-C (P = 0.03), and small apolipoprotein B100 (P = 0.04) than subjects with the APOA5*1 haplotype.
  
  
  CONCLUSIONS
  Our findings show that the presence of the APOA5*2 and APOA5*3 haplotypes in the APOA5 gene is associated with a higher postprandial response that could be involved in the higher risk of coronary heart disease associated with the 56G and -1131C alleles.
authors.affiliation: Unit of Lipids and Atherosclerosis, Hospital Universitario Reina Sofía, Avda Menéndez Pidal, Córdoba, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Moreno-Luna
authors.forename: Francisco
authors.initials: F
authors.lastname: Perez-Jimenez
authors.forename: Carmen
authors.initials: C
authors.lastname: Marin
authors.forename: Pablo
authors.initials: P
authors.lastname: Perez-Martinez
authors.forename: Purificacion
authors.initials: P
authors.lastname: Gomez
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Jimenez-Gomez
authors.forename: Javier
authors.initials: J
authors.lastname: Delgado-Lista
authors.forename: Juan A
authors.initials: JA
authors.lastname: Moreno
authors.forename: Toshiko
authors.initials: T
authors.lastname: Tanaka
authors.forename: Jose M
authors.initials: JM
authors.lastname: Ordovas
authors.forename: Jose
authors.initials: J
authors.lastname: Lopez-Miranda
mesh_terms: D000328:Adult; D000072040:Apolipoprotein A-V; D053299:Apolipoprotein B-100 / Q000235:genetics / Q000378:metabolism; D053283:Apolipoprotein B-48 / Q000235:genetics / Q000378:metabolism; D001054:Apolipoproteins A / Q000235:genetics* / Q000378:metabolism*; D003327:Coronary Disease / Q000208:ethnology / Q000235:genetics; D004734:Energy Metabolism / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D019518:Postprandial Period / Q000502:physiology*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D044465:White People / Q000235:genetics
chemical_list: C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001054:Apolipoproteins A; D008074:Lipoproteins; D014280:Triglycerides